<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02979912</url>
  </required_header>
  <id_info>
    <org_study_id>PEDUJCTC</org_study_id>
    <nct_id>NCT02979912</nct_id>
  </id_info>
  <brief_title>Autologous Platelet Lysate in Corneal Epithelial Defects</brief_title>
  <official_title>The Use of Autologous Platelet Lysate in Persistent Corneal Epithelial Defects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanan Jafar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Jordan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients diagnosed with persistent corneal epithelial ulcers will be treated with autologous
      platelet lysate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autologous platelet lysate (PL) will be given to patients diagnosed with persistent corneal
      epithelial ulcers (PED) who are unresponsive to conventional therapy to promote the healing
      of PED. PL will be dispensed into sterile eye droppers, and these eye droppers will be stored
      ideally at âˆ’20C and thaw once for use, then will be kept in the refrigerator at +4C, to be
      taken in multiple doses.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 16, 2017</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) as a result of the eye drops</measure>
    <time_frame>2 months</time_frame>
    <description>Evaluation of the safety and tolerability of PL in the treatment of PED by monitoring any adverse event resulting from the eye drops.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the efficacy by clinical judgment</measure>
    <time_frame>6 months</time_frame>
    <description>Efficacy of the given eye drops will be clinically evaluated by measuring the degree of healing of the epithelial defect</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Persistent Corneal Epithelial Defect</condition>
  <arm_group>
    <arm_group_label>Platelet Lysate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous platelet lysate dispensed into eye droppers to be applied four times a day for a total of four weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Platelet Lysate</intervention_name>
    <description>Eye drops of Platelet Lysate</description>
    <arm_group_label>Platelet Lysate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Cognitive ability to understand and sign the consent form.

          2. Corneal ulcers that did not re-epithelialise after 1 week of conventional treatment
             (therapeutic contact lenses, topical artificial tears, eye packs and antibiotic
             eye-drops).

          3. Clinical indications: corneal ulcer due to caustic substances, corneal epitheliopathy,
             corneal lesions following cataract surgery, recurrent ulcerative keratitis, corneal
             lesions due to a foreign body.

          4. Good compliance with the study regimen and availability for the duration of the entire
             study period.

        Exclusion Criteria:

          1. Corneal ulcers which developed tissue scars.

          2. Pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>78 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdallah Awidi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cell Therapy Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hanan Jafar, PhD</last_name>
    <phone>00962798871087</phone>
    <email>hanan.jafar@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cell Therapy Center</name>
      <address>
        <city>Amman</city>
        <zip>11942</zip>
        <country>Jordan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdalla Awidi, MD</last_name>
      <phone>0096265355000</phone>
      <phone_ext>23960</phone_ext>
      <email>abdalla.awidi@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Jordan</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2016</study_first_submitted>
  <study_first_submitted_qc>November 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2016</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Jordan</investigator_affiliation>
    <investigator_full_name>Hanan Jafar</investigator_full_name>
    <investigator_title>Researcher</investigator_title>
  </responsible_party>
  <keyword>Persistent corneal epithelial defect</keyword>
  <keyword>Platelet Lysate</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

